Table 1
From: Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
Set | HR(TTP) | Log-rank p-value | HR(OS) | Log-rank p-value |
|---|---|---|---|---|
DEV | 0.48 | 0.020 | 0.026 | 0.005 |
VAL | 0.43 | 0.013 | 0.48 | 0.012 |
Full SET1 | 0.50 | 0.001 | 0.38 | <0.001 |
SET2 | n/a | n/a | 0.26 | 0.002 |